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Although the prognosis for children with Wilms’ tumour improved
steadily from the 1960s until the early 1980s, there has been rela-
tively little progress, so far as treatment intensity is concerned,
since then. With overall long-term survival now exceeding 80%,
investigators have instead invested their efforts into planned
reduction of both short- and long-term toxicities, especially in
those patients – fortunately the majority – who have biologically
favourable disease. The second national United Kingdom
Children’s Cancer Study Group (UKCCSG) Wilms’ tumour study
(UKW2), reported here, is an example of this genre of studies.
The Medical Research Council, who conducted two trials,
MRC1 from 1970–1974 (Lennox et al, 1979) and MRC2 from
1974–1978; (Morris Jones et al, 1987) initiated national treatment
studies for Wilms’ tumour in the UK. MRC1 and MRC2 enrolled
108 and 144 patients respectively, aged over 1 year with non-
metastatic disease, all of whom were treated with nephrectomy,
abdominal radiotherpay and then chemotherapy. More than 70%
of patients in MRC1 were still alive at 3 years, an encouraging
result for that era. The 62 stage 1 patients in MRC2 were random-
ized to receive either 6 months or 2 years of single-agent actino-
mycin D. The outcome for the two groups was identical with a
3-year survival of 86%. The 82 stage II and III patients were
randomized to either a 2-drug regimen (vincristine and actino-
mycin D) or 3-drug regimen (these two drugs plus doxorubicin)
after nephrectomy and postoperative radiotherapy. The outcome
for the two groups was identical.
The results for stage I patients in MRC2 conflicted with an
earlier US study in which there appeared to be an advantage to a
longer course of treatment, albeit at a lower dose intensity
(D’Angio et al, 1976). The stage II and III results also conflicted
with the findings of a similar randomization in the much larger
National Wilms’ Tumour Study (NWTS) 2 trial, which demon-
strated an advantage for patients receiving a similar 3-drug
regimen (D’Angio et al, 1981).
The UKCCSG assumed responsibility for UK national Wilms’
tumour trials in 1979. Its first study, ‘UKW1’, included all
patients with all stages and histological subtypes of Wilms’
tumour. Children with metastatic disease at diagnosis (stage IV)
and those with clear cell sarcoma (CCSK) and rhabdoid tumours
(RTK) were also included (Pritchard et al, 1995). The main objec-
tive of UKW1 for favourable histology (FH) patients was to
determine whether treatment could be reduced in stages I and II
patients without compromising cure rates, and whether intensifi-
cation of therapy for stage III and IV and unfavourable histology
(UH) patients could improve prognosis. This study demonstrated
that for stage 1 FH patients, single-agent vincristine was as effec-
tive as vincristine and actinomycin D, and that fractionation of
actinomycin D was unnecessary. The results for children with
stage III tumours were comparable to those of contemporary
NWTS trials, but those for stage IV and UH Wilms’ patients
seemed to be inferior to those of the NWTS studies, either
because of differences in treatment or in case selection bias or
both. The results for children with CCSK and RTK were similar
to those achieved by the NWTS.
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Summary The aims of the UKW2 study were: (1) to further refine treatment for stage I and II favourable histology (FH) patients; (2) to
consolidate the UKW1 results for stage III FH patients; (3) to improve the outlook for patients with inoperable primary tumours and those
patients with stage IV and unfavourable histology disease. Treatment consisted of primary nephrectomy, wherever possible, followed by
chemotherapy and radiotherapy, as dictated by stage and histology. Treatment was refined successfully for stage I and II FH patients. The 4-
year event-free survival for these two groups was 94% and 91%, respectively. Stage III FH patients had a 4-year event free survival of 84%.
The outlook for patients with clear cell sarcoma of the kidney is as good as for patients with favourable histology, whilst that for patients with
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doi: 10.1054/ bjoc.2000.1338, available online at http://www.idealibrary.com on The aims of UKW2 were to:
1. explore the possibility of further refinements in treatment for
stage I and II FH patients, by reducing the duration of single-
agent vincristine treatment for stage I patients from 6 months
to 10 weeks and by omitting radiotherapy for stage II patients
2. consolidate the UKW1 results for stage III FH patients who
received the same treatment as in UKW1 (Pritchard et al,
1995)
3. improve the outlook for patients with inoperable primary
tumours and those patients with stage IV and UH disease,
including RTK and CCSK, by intensification of chemotherapy
and addition of radiotherapy.
METHODS
Patient eligibility, histology and staging
All the then-20 constituent centres of the UKCCSG (see
Appendix) participated in the study from its inception in July 1986
until its closure in September 1991. In all cases the diagnosis of
Wilms’ or other renal tumour was confirmed histopathologically,
either from the nephrectomy specimen or, in those patients whose
tumours were deemed inoperable, by open or closed needle biopsy.
All UK-based children with newly diagnosed Wilms’ tumour diag-
nosed prior to their 15th birthday were eligible, including patients
with metastatic or bilateral tumours. The only exclusions were
those patients who had previously received treatment for Wilms’
tumour.
Nephrectomy was the initial treatment in all patients except
those with stage IV or inoperable tumours. The ‘local’ pathologist
initially determined the abdominal stage and histology of each
tumour. Multiple blocks were taken from each tumour (a minimum
of ten was recommended) around its maximum circumference, as
well as from areas where there was suspicion of tumour spread
beyond the pseudocapsule. All excised lymph nodes were exam-
ined. Subsequently, histopathological sections were reviewed by a
panel of pathologists and classified as Wilms’ tumour (WT)
favourable histology (FH); anaplastic WT (focal or diffuse); rhab-
doid tumour (RTK), clear cell sarcoma (CCSK or bone-metasta-
sizing renal tumour), mesoblastic nephroma, renal cell carcinoma
or primitive neuroectodermal tumour. The staging system and
histological subtyping were those used in UKW1 and correspond
to those used in the NWTS 3 and NWTS 4 studies (D’Angio et al,
1989; Green et al, 1995).
Other investigations for all patients included abdominal ultra-
sound or CT scan, and postero-anterior plus lateral chest X-rays
(CXR). CT scans of the chest were performed in a number of
patients, but metastases visible on plain CXR were required for
patients to be classified as stage IV. Isotopic or radiological
skeletal surveys were required only in those patients with CCSK.
Cranial CT scans were recommended for patients with rhabdoid
tumours. Renal angiography and intravenous urogram were
optional. Based on the staging investigations, the surgical and
pathological findings and the criteria established by the NWTS,
patients were classified as having either FH or UH tumours, stages
I, II, III or IV, or bilateral primary tumours. ‘Inoperable’ non-
metastatic tumours were considered to be stage III.
Treatment plan
All patients without metastases at diagnosis were, if the tumour
was deemed operable by the local surgeon, to have initial surgery.
All patients received chemotherapy according to their surgical
stage. In addition all stage III and IV patients were to receive
radiotherapy to the tumour bed and/or sites of abdominal or lung
metastases. The overall treatment strategy and details of the
chemotherapy are shown in Table 1.
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Table 1 Overall treatment plan and details of chemotherapy
Histology/stage Surgery Radiotherapy Chemotherapy
Favourable histology
I Initial None VCR only
II Initial None VCR + ActD
III Initial 20 Gy, hemi-abdomen Non-intensive VCR + ActD + doxo
IV Delayed If local stage III 30 Gy to hemi-abdomen; Intensive VCR + ActD + doxo
12 Gy to whole lung
Unfavourable histology
I Initial None Intensive VCR + ActD + doxo
II Initial None Intensive VCR + ActD + doxo
III Initial 30 Gy to hemiabdomen Intensive VCR + ActD + doxo
IV Delayed If local stage III 30 Gy to hemi-abdomen; Intensive VCR + ActD + doxo
12 Gy to whole lung
Inoperable tumours, Delayed 30 Gy to hemi-abdomen, if Intensive VCR + ActD + doxo
any histology local stage III at time of surgery
FH Stage I: 10 weekly injections of VCR 1.5 mg m–2 as a single agent.
FH Stage II: 11 weekly injections of VCR, then 3-weekly for five further doses, together with ActD every 3 weeks starting at week 2 for a total of nine doses.
Total duration of treatment, 6 months.
FH Stage III: 10 weekly doses of VCR, followed by 14 further doses at 3-weekly intervals; ActD 0.75 mg m–1 at week 2 just prior to radiotherapy and then 1.5
mg m–2 at week 10 then at 6-weekly intervals until week 52; doxo 40 mg m–1 at 6-weekly intervals alternating with ActD, starting at week 7. Total duration of
treatment, 12 months.
FH Stage IV: 11 weekly injections of VCR, then 3-weekly for five further doses, together with ActD every 3 weeks starting at week 2 for a total of nine doses
concurrently with doxo 30 mg m–1. Total duration of treatment, 6 months.
UH Stage III and primarily inoperable tumours: as for UH stages I and II. Total duration of treatment, 12 months.
VCR = vincristine; ActD = actinomycin D; doxo = doxorubicinSurgery
Initial surgery, i.e. surgery at the time of diagnosis, was recom-
mended for all patients unless the operation was deemed too risky,
or complete tumour excision could probably not be achieved. In
this case, and for patients with metastases detected at the time 
of diagnosis, patients received three-drug chemotherapy and 
had a delayed nephrectomy at approximately week six.
Recommendations for surgery were identical to those used in
UKW1 (Pritchard et al, 1995).
Chemotherapy
Details of chemotherapy are given in Table 1.
Radiotherapy
Abdomen
Patients with operable FH stage III tumours were to be given 
20 Gy (10 × 2 Gy) to the midplane of the tumour over 2 weeks
starting within 14 days of surgery. Patients with delayed surgery
did not receive any radiotherapy if there was no viable tumour at
the time of surgery but received 30 Gy (15 × 2 Gy) to the flank if
viable tumour was present.
Lung
Whole-lung irradiation was to be given to all patients with metas-
tases present on chest X-ray at the time of diagnosis. Radiotherapy
was given immediately after surgery and concurrently with
abdominal radiotherapy if also indicated. Treatment consisted of
12 Gy to the midplane of the lungs, given as 8 × 1.5 Gy fractions.
Data collection and analysis
Data on all patients with renal tumours treated in UKCCSG centres,
representing more than 90% of all childhood renal tumours diag-
nosed in the UK during the 63-month period of UKW2 (Stiller et al,
unpublished), was collected centrally and reviewed by the study
coordinators. Survivals were calculated by the method of Kaplan
and Meier (1958). The log-rank test (Peto et al, 1977) was applied
to evaluate the significance of established prognostic factors –
stage, histological subtype and age-group (< 1 year, 1–4 years and 
> 5 years). Survival time was defined as the time from diagnosis to
death from any cause, or to date of last follow-up. Event-free
survival was defined as the time from diagnosis to first
relapse/progression, time to death or date of last follow-up.
The local centre determined the tumour stage according to
NWTS criteria. Subsequent central review was also carried out.
Assessment of agreement between ‘local’ and ‘central’ review
panels used the kappa statistic (Brennan and Silman, 1992).
RESULTS
Between June 1986 and September 1991, UKCCSG centres regis-
tered a total of 447 consecutively diagnosed eligible patients with
renal tumours. Three patients with extra-renal tumours were
included but not allocated a stage. Analysis followed the ‘intention
to treat’ principles, i.e. patients with protocol deviations were
included. Brief details of the patients with unfavourable histology
are given here, but will be more comprehensively reported by
Kelsey et al (in preparation).
The male:female ratio was 207:240 (0.86:1) and the age-range
at diagnosis was 0–15.4 years (median 2.71 years). Of the 46 UH
patients, 20 were boys. No gender preponderance was noted in the
group with CCSK (8 boys, 8 girls).
Twenty UKCCSG centres entered patients in the study, median
18 patients, range 1–100 (see Appendix). One centre entered a
single patient, 12 centres entered fewer than 20 patients and eight
centres 20 patients or more. There was no indication of any differ-
ence between the large and small centres in overall survival (OS)
(P = 0.86) or event-free survival (EFS) (P = 0.59). Outcomes were
also similar when only Wilms’ patients were considered, with P-
values of 0.77 and 0.30 for OS and EFS, respectively.
Stage
The stage distribution of patients with favourable and other
histologies is given in Tables 2 and 3 respectively. The three
patients with extra-renal tumours were not allocated a stage and so
cannot be included in the stage-related analysis. There were 23
patients with bilateral tumours who are included in the analysis,
but have been more fully described previously (Kumar et al,
1998).
Survival
Patients have been followed-up to April 1998, a median of 103
months (range 3–139 months) since diagnosis. There have been 70
deaths in all, 63 from tumour, three from treatment complications
and four from other causes. The 2-year and 4-year estimates of
overall and event-free survival by stage for 398 FH patients are in
Table 4. As expected, stage is significantly correlated with both
EFS and OS with log-rank test P-values for differences in survival
between stages of P = 0.05 for EFS and P = 0.0008 for OS.
Histology
According to the local pathologists’ reports, there were 401
favourable histology (FH) patients and 46 unfavourable histology
(UH) patients (17 clear cell sarcoma (BMRTC), 20 anaplastic,
nine rhabdoid). In just one patient the histology showed Wilms’
tumour but the subtype could not be determined.
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Table 2 Stage distribution for 398 favourable local histology patients
Stage n (%)
I 136 (34)
II 57 (14)
IIIa 122 (31)
IV 60 (15)
V 23 (6)
aincludes 36 tumours initially unresectable
Table 3 Stage distribution for 46 unfavourable local histology patients
Stage Anaplasia CCSK RTK
I6 7 0
II 3 4 1
III 5 6 6
IV 6 0 2Histology, as assessed both locally and by the review panel,
significantly correlated with differences in outcome. Patients with
FH and CCSK fared better than patients with anaplastic tumours
and RTK (91 and 94% vs 55 and 33% respectively). For all 447
patients, the log-rank test for OS gave P < 0.0001, and for EFS P <
0.0001 for differences in outcome. Details of outcome by review
pathology are given in Table 5.
Age and gender
Age did not affect outcome. For the 401 FH patients, the log-rank
test for differences in outcome by age gave for overall survival
(OS) P = 0.69 (Trend test 0.45), and for event-free survival (EFS)
P = 0.81 (Trend test 0.97), (data not shown). Overall, girls fared
slightly less well than boys but the difference was not statistically
significant (data not shown). In multivariate analysis of all 447
patients, after adjustment of outcome for stage and histology, the
difference by gender is not significant for EFS (P = 0.12).
Stage
Three hundred and seventy four patients’ records were retrospec-
tively examined by central review. Review stage agreed with the
local assessment in 326 cases (87%), but differed in 48. The major
disagreement concerned the allocation to state II or III; some
patients had been mis-assigned a stage despite clear pathological
reports to the contrary. In some instances the pathologist had indi-
cated an incorrect stage, while in others the treating oncologist had
drawn an erroneous conclusion from the pathologist’s report.
Some patients initially assigned to stage IV were reassigned to
stages I–III because there was no record of metastatic deposits
either on plain chest radiographs or at laparotomy. Two patients
were assigned to stage IV because of lung metastases detected
solely on CT scan (Owens et al, in preparation).
Kappa analysis (Brennan and Silman, 1992) evaluates how
much better agreement between local and review assessments are
than chance. Conventionally, a value above 0.8 is taken as ‘very
good’ agreement, and above 0.6 as ‘good’ agreement. Overall
there is very good agreement particularly for stage I and bilateral
tumours. Eleven of 55 stage II patients (local assessment) should
have been upstaged to III, but only 11/116 patients were mistak-
enly upstaged locally from stage I or II to stage III locally. Details
of this analysis are shown in Table 6.
Histology
Material from 381 patients was available for central review. In 366
cases review histology agreed with the local assessment (96%).
According to the pathology review panel, there were 43
unfavourable histology (UH) cases (14 anaplastic Wilms’, 18
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Table 4 2-year and 4-year estimates of overall survival and event-free survival for 398 favourable
histology patients, stratified according to local histology and staging
Stage n (%) 2-year OS 2-year EFS 4-year OS 4-year EFS
(% [95% CI]) (% [95% CI]) (% [95% CI]) (% [95% CI])
I 136 (34) 96 [91–98] 89 [83–93] 94 [89–97] 87 [80–91]
II 57 (14) 95 [85–98] 82 [72–92] 91 [81–96] 82 [70–90]
III 122 (31) 90 [84–94] 83 [75–88] 84 [77–90] 82 [74–88]
IV 60 (15) 82 [70–89] 72 [59–82] 75 [63–84] 70 [57–80]
Bilateral 23 (6) 83 [63–93] 70 [49–84] 78 [58–90] 70 [49–84]
Table 5 2-year and 4-year overall survival and event-free survival by ‘review’ histology
Review 2-year OS 2-year EFS 4-year OS 4-year EFS
histology n (%) (% [95% CI]) (% [95% CI]) (% [95% CI]) (% [95% CI])
All favourable
histology 338 91 [87–93] 83 [79–87] 87 [83–90] 82 [77–86]
Clear cell
sarcoma 18 88 [66–97] 82 [59–94] 88 [66–97] 82 [59–94]
Anaplastic 14 64 [39–84] 36 [16–61] 50 [27–73] 29 [11–56]
Rhabdoid 11 36 [15–65] 36 [15–65] 36 [15–65] 36 [15–65]
Table 6 Comparison between ‘local’ and ‘review’ tumour stage for 374 patients
Review stage
Local I II III IV Bilateral Kappa
stage
I 124 4 1 0 0 0.90
II 6 38 11 0 0 0.65
III 2 9 105 0 0 0.81
IV 3 3 8 45 0 0.84
Bilateral 1 0 0 0 14 0.96
Overall Kappa ––– ––0.82CCSK, 11 RTK), 338 favourable histology (FH) and 67 patients
with insufficient material for definitive conclusions. For all
reviewed patients, differences in outcome by review histology
were highly significant (log-rank test: OS P < 0.0001, and EFS 
P < 0.0001).
By kappa analysis there was very good overall agreement
between local and review assessment, particularly for clear cell
sarcoma and rhabdoid tumours. Five (30%) of the 16 tumours
designated by the local pathologist as anaplastic were regarded as
FH by the review panel, whilse seven of 339 tumours identified
locally as FH were classified as UH on review. Nevertheless, the
survival outcome for all histological subtypes is similar whether
analysed by local or central review.
DISCUSSION
Investigators agree that outcome is likely to be good for Wilms’
patients with no unfavourable histological features and no imaging
evidence of metastasis – in other words those with stage I, II and
III FH tumours (Green et al, 1996a; Godzinski et al, 1999).
Children with stage I tumours with focal anaplasia and, so long as
doxorubicin is included in the treatment regimen, CCSK, also
have a good prognosis. Patients with FH tumours but radiological
(CXR) evidence of metastatic disease in the lungs or elsewhere
(stage IV) have a moderate outlook, whereas those with stages II,
III and IV RTK have a poor prognosis. Recent Wilms’ tumour
trials have shared objectives – to reduce toxicity, especially ‘late
effects’ of treatment, in patients with a relatively good prognosis,
and to improve survival particularly in those with a less favourable
prognosis. The UKW2 trial was no exception. Comparisons with
NWTS trials are straightforward, given the similarities in
approach. Comparisons with SIOP trials, though, are made diffi-
cult by differences in patient stratification and the use of preopera-
tive chemotherapy.
The results of UKW2 show, as do UKW1, NWTS 1, 2, 3 and 4
and recent SIOP studies, that treatment for patients with good prog-
nosis can be successfully refined without prejudicing survival, or
even the rate of relapse (D’Angio et al, 1976; 1981; 1989; Tournade
et al, 1993; Green and Coppes 1995; Pritchard et al, 1995;
Godzinski et al, 1999). About 90% of children with stage I FH
tumours (34% of all FH patients in UKW2) can be cured by radical
tumour removal and single-agent chemotherapy with only 10
weekly doses of vincristine. Results in UKW2 are virtually the same
as those obtained in the contemporary NWTS3: 4-year EFS 87 vs
91.8%, and 4-year OS 94 vs 97.4% using 6 months of vincristine
and actinomycin D. Thus, in these patients, the risk of actinomycin
D-induced hepatotoxicity (Green et al, 1988; Raine et al, 1991;
Ludwig et al 1992), which can be life-threatening, can be avoided,
as can myelosuppression with its attendant risks, and alopecia.
More than 90% of stage II FH patients can also be cured with 6
months of two-drug treatment using vincristine and actinomycin
D, without exposing them to the risks of treatment with radio-
therapy or doxorubicin. Similar results were seen in NWTS3,
where ‘intensive’ actinomycin D with vincristine was seen to be as
good as three-drug chemotherapy, and the addition of 20 Gy radio-
therapy did not significantly improve outcome. In both stage I and
stage II patients, therefore, the objectives of UKW2 were
achieved.
Stage III patients in UKW2 were treated in exactly the same
manner as UKW1, with three-drug chemotherapy (vincristine,
actinomycin D and doxorubicin) and 20 Gy abdominal radio-
therapy, usually to the hemiabdomen. In UKW1, subset analysis
suggested that patients with tumours designated ‘stage III’ only by
virtue of microscopic tumour at resection margins fared better than
those with visible tumour residue or positive abdominal lymph
nodes or both (UKCCSG, unpublished observation). This observa-
tion led one UKCCSG centre to conduct, during UKW2, a sepa-
rate pilot study in which radiotherapy was omitted successfully
from the treatment of its stage III patients < 3 years-of-age at diag-
nosis, judged as particularly vulnerable to troublesome ‘late
effects’ from radiotherapy (Pachnis et al, 1998). The results of our
analysis of stage III results from UKW2 will be published sepa-
rately.
Survival for stage IV FH patients was better in UKW2 than in
UKW1, but the comparison is historical and there may be a
number of explanations for the difference. The growing overall
experience of Wilms’ tumour management in UKCCSG centres
might, for instance, be critical, as might the inclusion of whole-
lung irradiation in children with lung metastases. Even though the
treatment plan was similar, UKW results for stage IV patients are
apparently inferior to those reported in NWTS studies (D’Angio et
al, 1989; Pritchard et al, 1995; Green et al, 1996b). However, of
the 59 patients assessed locally as stage IV, only 37 had whole-
lung radiotherapy as prescribed by the protocol. Superficially,
there is a clear case for whole-lung radiotherapy in the treatment of
lung metastases in Wilms’ tumour. The SIOP group, however,
have reported survival of over 80% in stage IV patients without
systematic use of pulmonary radiotherapy (De Kraker et al, 1990),
and 50% of stage IV patients in UKW1 were cured without its use
(Pritchard et al, 1995). It is possible that with careful selection of
patients and greater use of pulmonary resection, the proportion of
patients receiving pulmonary radiotherapy might be reduced
without prejudicing their chances of survival, but whether such a
development is warranted, given the minimal long-term conse-
quences of 12 Gy of pulmonary radiotherapy, is questionable. A
more relevant question might be the identification of patients who
could be successfully treated with less doxorubicin, thus obviating
the potential long-term side-effects of anthracycline therapy,
particularly when given in conjunction with whole-lung radio-
therapy (Lipshultz et al, 1991; Sorensen et al, 1995). The NWTS
concluded that there was a subgroup of stage IV patients who
could be successfully treated without doxorubicin (Green et al,
1996b). The NWTS have also now demonstrated that treatment for
stage III and IV tumours can be shortened, and hence the cumula-
tive dose of doxorubicin reduced, without prejudicing outcome
(Green et al, 1998).
Except for CCSK patients, whose cure rate overall is now as
good that for FH patients, results for children with unfavourable
histology renal tumours are still disappointing. Patients with
anaplastic tumours have a 4-year EFS of around only 30%. Data
from NWTS3 suggested that stage II–IV patients with anaplasia
might benefit from the addition of cyclophosphamide, although
this difference was not significant once allowance had been made
for the number of patients with only focal anaplasia receiving this
additional drug. Children with RTK have an appalling prognosis
unless they have a stage I tumour. Better treatments are urgently
needed for these patients.
The histology and stage review in this study was carried 
out after it had closed, and for the purposes of verifying the
accrued data. It was not intended as a method of ensuring rigorous
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adherence to the protocol. Nevertheless, the differences in ‘local’
and ‘review’ staging emphasize the need for particular care in this
process. Patients treated for a lower-stage tumour than they actu-
ally have will have an increased risk of recurrence. In this study,
16 of 374 patients were understaged, of whom 12 ought to have
been stage III and who therefore did not receive have doxorubicin
and flank irradiation. Conversely, 29 of 374 patients were over-
staged, of whom 24 received doxorubicin and radiotherapy with
their attendant long-term toxicities. Thus 12% of patients overall
had incorrect staging. Histology was more accurate, with local and
review opinions differing in only 14 (3%) out of 380 cases. Future
studies probably ought to include some method for rapid review of
pathology and stage to ensure the highest standards of protocol
compliance.
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